Compare BKE & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKE | STOK |
|---|---|---|
| Founded | 1948 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 1996 | 2019 |
| Metric | BKE | STOK |
|---|---|---|
| Price | $45.48 | $32.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $53.00 | $39.20 |
| AVG Volume (30 Days) | 447.3K | ★ 617.0K |
| Earning Date | 05-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | 6.43 | ★ 92.73 |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $1,297,835,000.00 | $184,420,000.00 |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $4.99 | $77.49 |
| P/E Ratio | $49.55 | ★ N/A |
| Revenue Growth | 6.58 | ★ 404.50 |
| 52 Week Low | $40.73 | $12.86 |
| 52 Week High | $61.69 | $40.22 |
| Indicator | BKE | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | N/A |
| Support Level | $41.15 | N/A |
| Resistance Level | $56.21 | N/A |
| Average True Range (ATR) | 1.09 | 0.00 |
| MACD | 0.45 | 0.00 |
| Stochastic Oscillator | 94.21 | 0.00 |
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.